Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP | Zendy

Salla Lahdenpohja | Zendy; Noora Rajala | Zendy; Jatta S. Helin | Zendy; Merja HaaparantaSolin | Zendy; Olof Solin | Zendy; Francisco R. López-Picón | Zendy; Anna K. Kirjavainen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ruthenium-Mediated ¹⁸F-Fluorination and Preclinical Evaluation of a New CB₁ Receptor Imaging Agent [¹⁸F]FPATPP

Author(s) -

Salla Lahdenpohja,

Noora Rajala,

Jatta S. Helin,

Merja HaaparantaSolin,

Olof Solin,

Francisco R. López-Picón,

Anna K. Kirjavainen

Publication year - 2020

Publication title -

acs chemical neuroscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.158

H-Index - 69

ISSN - 1948-7193

DOI - 10.1021/acschemneuro.0c00313

Subject(s) - chemistry , positron emission tomography , ruthenium , radiochemistry , cannabinoid receptor , pet imaging , cannabinoid , specific activity , receptor , metabolic stability , yield (engineering) , nuclear medicine , biochemistry , medicine , enzyme , in vitro , physics , antagonist , catalysis , thermodynamics

Cannabinoid receptor 1 (CB1R) controls various physiological and pathological conditions, including memory, motivation, and inflammation, and is thus an interesting target for positron emission tomography (PET). Herein, we report a ruthenium-mediated radiolabeling synthesis and preclinical evaluation of a new CB1R specific radiotracer, [ 18 F]FPATPP. [ 18 F]FPATPP was produced with 16.7 ± 5.7% decay-corrected radiochemical yield and >95 GBq/μmol molar activity. The tracer showed high stability, low defluorination, and high specific binding to CB1Rs in mouse brain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research